A
Alvotech
Dedicated to broadening the availability and accessibility of biosimilars
About Alvotech
Alvotech is a biopharmaceutical company that specializes in the development and manufacturing of biosimilars, which are essentially less expensive versions of biologic medicines. These medicines are used in the treatment of a variety of diseases, making Alvotech's work crucial in the healthcare sector. The company's primary goal is to improve lives by making biologic medicines more accessible and affordable.
Alvotech operates in the global pharmaceutical market, serving a wide range of clients, including healthcare providers and patients. The company's business model is vertically integrated, meaning it controls every stage of the process, from cell line development to the final stages of manufacturing. This approach allows Alvotech to maintain control, scale operations, and speed up the production process, thereby enhancing efficiency and cost-effectiveness.
The company generates revenue by selling its high-quality, cost-competitive biosimilars to healthcare providers worldwide. Alvotech also continually evaluates additional pipeline opportunities to expand its selection of biologic medicines, which could potentially lead to increased revenue streams.
Alvotech's recent financial results and business updates indicate positive growth and development, with the company announcing positive top-line results from a pharmacokinetic study for a proposed biosimilar. This suggests that Alvotech is not only maintaining its current operations but also actively pursuing new opportunities for growth and expansion.
In summary, Alvotech is a purpose-driven biopharmaceutical company that aims to improve lives by making biologic medicines more accessible and affordable.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- Public via SPAC 2021
Open roles
Alvotech in the Reykjavík ecosystem
The Alvotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Fuji Pharma
Series B and later16 investors entered at this stage
CVC Capital Partners
Sculptor
Suvretta Capital Management
Farallon Capital Management
Temasek
Arion banki
Landsbankinn
Athos
Arctica Finance- OIOaktree Acquisition Corp. II
- AVATHOS Venture
Oaktree Capital Management
Lodbrok Capital
Morgan Stanley
Alvogen
GoldenTree Asset Management
Source: Dealroom Talent Intelligence.
Patents
4 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Alvotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Alvotech gets FDA approval for new SIMLANDI process that more than doubles output per batch
FDA approves second U.S.-supply manufacturing suite for Alvotech's SIMLANDI biosimilar
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal
